MarketCap
Facebook
X
Telegram
Eargo Net Income | EAR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -157 M | -158 M | -39.9 M | -44.5 M | -33.8 M | -24.6 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -24.6 M | -158 M | -76.3 M |
Quarterly Net Income Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.3 M | -25.2 M | -21.9 M | - | -50.6 M | -32.4 M | -30.6 M | - | -79.3 M | -19.3 M | -13.6 M | - | -9.73 M | -6.59 M | -11.7 M | - | -12.2 M | -9.76 M | -9.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -6.59 M | -79.3 M | -23.3 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Medtronic PLC
MDT
|
4.8 B | $ 95.41 | -1.18 % | $ 122 B |  USA |
 |
Sientra
SIEN
|
-22 M | - | -16.59 % | $ 10.3 M | USA |
 |
AxoGen
AXGN
|
-15.7 M | $ 38.06 | 3.76 % | $ 1.75 B | USA |
 |
Silk Road Medical, Inc
SILK
|
-55.7 M | - | - | $ 1.07 B | USA |
 |
Myomo
MYO
|
-15.6 M | $ 1.21 | -0.82 % | $ 50.6 M | USA |
 |
Surgalign Holdings
SRGA
|
-54.6 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
147 M | - | - | $ 12.3 B | USA |
 |
Bio-Rad Laboratories
BIO
|
760 M | $ 369.95 | 1.68 % | $ 10.1 B | USA |
 |
Abiomed
ABMD
|
137 M | - | - | $ 17.2 B | USA |
 |
Titan Medical
TMDI
|
-14.9 M | - | -26.32 % | $ 19.6 M |  Canada |
 |
Natus Medical Incorporated
NTUS
|
13.2 M | - | 1.94 % | $ 1.05 B | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Outset Medical
OM
|
-81.7 M | $ 4.1 | -1.68 % | $ 62.4 K | USA |
 |
Bruker Corporation
BRKR
|
-8.3 M | $ 57.59 | 0.49 % | $ 8.74 B | USA |
 |
Boston Scientific Corporation
BSX
|
2.89 B | $ 45.69 | -0.7 % | $ 67.6 B | USA |
 |
Inari Medical
NARI
|
-1.64 M | - | - | $ 4.23 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
PAVmed
PAVM
|
-3.77 M | $ 2.17 | 5.85 % | $ 1.45 M | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 149.01 | 0.6 % | $ 10.5 B | USA |
 |
Profound Medical Corp.
PROF
|
-42.6 M | $ 5.56 | -3.47 % | $ 168 M | Canada |
 |
AVITA Medical
RCEL
|
-48.6 M | $ 15.51 | 0.58 % | $ 432 M |  Australia |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
40.4 M | - | - | $ 2.07 B | USA |
 |
Butterfly Network
BFLY
|
-77.1 M | $ 6.76 | -0.81 % | $ 1.67 B | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 9.14 | -1.19 % | $ 259 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 1.58 | -3.66 % | $ 4.38 M | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 49.25 | -0.11 % | $ 1.53 B | USA |
 |
Smith & Nephew plc
SNN
|
625 M | $ 30.83 | -0.11 % | $ 26.7 B |  Britain |
 |
Sensus Healthcare
SRTS
|
-7.72 M | $ 2.95 | 1.55 % | $ 48.2 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 5.27 | -12.31 % | $ 328 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-6.09 M | - | - | $ 3.31 B | USA |
 |
ThermoGenesis Holdings
THMO
|
-18.9 M | - | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
-62 M | - | 3.55 % | $ 7.96 M | USA |
 |
Viveve Medical
VIVE
|
-22 M | - | -15.35 % | $ 1.71 M | USA |
 |
Tandem Diabetes Care
TNDM
|
-205 M | $ 17.43 | 1.63 % | $ 1.19 B | USA |
 |
ViewRay
VRAY
|
-107 M | - | 1.54 % | $ 468 M | USA |
 |
SmileDirectClub
SDC
|
-86.4 M | - | -53.45 % | $ 9.71 M | USA |
 |
Acutus Medical
AFIB
|
-9.55 M | - | -26.83 % | $ 2.62 M | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Viemed Healthcare
VMD
|
15.4 M | $ 9.8 | -1.21 % | $ 381 M | USA |
 |
Vapotherm
VAPO
|
-58.2 M | - | 6.72 % | $ 34 M | USA |
 |
Varex Imaging Corporation
VREX
|
-70.3 M | $ 18.42 | 0.05 % | $ 763 M | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
-54.3 M | - | 0.28 % | $ 270 M | USA |
 |
Vivos Therapeutics
VVOS
|
-21.2 M | $ 0.13 | 0.91 % | $ 1.34 M | USA |
 |
Zynex
ZYXI
|
2.99 M | - | - | $ 21.1 M | USA |
 |
Beyond Air
XAIR
|
-33.2 M | $ 2.09 | -9.1 % | $ 17.3 B | USA |
 |
Xtant Medical Holdings
XTNT
|
4.97 M | $ 0.28 | -11.28 % | $ 39.1 M | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |